BriaCell Therapeutics has priced a best-efforts public offering of 5,366,726 units at $5.59 per unit, generating gross proceeds of approximately $30 million before fees and expenses. Each unit comprises one common share (or a pre-funded warrant in lieu) and one warrant exercisable at $6.93 per share for five years. The warrants have been approved for listing on the Nasdaq Capital Market under the symbol “BCTXL,” with trading expected to begin January 14, 2026. ThinkEquity is serving as the sole placement agent, and the offering is expected to close on January 15, 2026, subject to customary closing conditions. Net proceeds will support working capital, general corporate purposes and advancement of BriaCell’s clinical and preclinical programs.

In the ongoing Phase 1/2a study of Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy, a 78-year-old patient with hormone receptor-positive, HER2-negative metastatic breast cancer achieved a sustained complete resolution of a lung metastasis over 11 months. The complete response was first confirmed at two months and sustained through four, six and eleven months following 17 cycles of monotherapy. No treatment-limiting toxicities were reported, and the patient’s other evaluable lesions remained stable. With the dose-escalation portion complete, the trial has now advanced into the Phase 2a cohort evaluating Bria-OTS in combination with an immune checkpoint inhibitor.